TEVA Stock: Price, Earnings History and SEC Filings
Teva Pharmaceutical Industries Limited (TEVA) last traded at $42.09, up 1.50% on the latest session and up 6.3% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.00 against an analyst estimate of $0.05, a miss of 100.0%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
TEVA earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 29, 2026 | $0.00 | $0.05 | -100.00% |
| Mar 2026 | Apr 29, 2026 | $0.50 | $0.49 | +2.04% |
| Dec 2025 | Jan 28, 2026 | $0.93 | $0.63 | +47.62% |
| Sep 2025 | Nov 5, 2025 | $0.75 | $0.66 | +13.64% |
TEVA beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How TEVA reacts to earnings
Across its last 8 earnings releases, TEVA moved 8.9% on average the next session, in either direction. It rose after 7 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-29 | Before open | +9.60% |
| 2026-04-29 | Before open | +11.89% |
| 2026-01-28 | Before open | +2.09% |
| 2026-01-12 | Before open | +2.44% |
| 2025-11-05 | Before open | +20.23% |
| 2025-07-30 | Before open | +1.75% |
| 2025-05-07 | Before open | +9.18% |
| 2025-01-29 | Before open | -13.89% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
TEVA financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $17.3B | $1.4B | – | 8.2% | $1.21 |
| 2024 | $16.5B | -$1.6B | – | -9.9% | $-1.45 |
| 2023 | $15.8B | -$559M | – | -3.5% | $-0.50 |
| 2022 | $14.9B | -$2.4B | $1.0B | -16.4% | $-2.20 |
| 2021 | $15.9B | $417M | $236M | 2.6% | $0.38 |
| 2020 | $16.7B | -$4.0B | $638M | -24.0% | $-3.64 |
| 2019 | $16.9B | -$999M | $223M | -5.9% | $-0.91 |
| 2018 | $18.3B | -$2.1B | $1.8B | -11.8% | $-2.35 |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for TEVA
- 8-K · Oct 29, 2026Officer or director change
- 8-K · Sep 16, 2026Material agreement, New financial obligation, Financial statements and exhibits
- 8-K · Sep 14, 2026Other events
- 424B5 · Sep 11, 2026
- 8-K · Sep 11, 2026Regulation FD disclosure, Other events, Financial statements and exhibits
- 424B5 · Sep 8, 2026
- 8-K · Sep 3, 2026Other events, Financial statements and exhibits
- 8-K · Sep 3, 2026Financial statements and exhibits
- 10-Q · Jul 29, 2026
- 8-K · Jul 29, 2026Results of operations, Financial statements and exhibits
Insider filing activity
TEVA insiders filed 8 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
TEVA news
- Teva: I Still See Upside After A Massive RallyOct 31, 2026 · seekingalpha.com
- Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In DealmakingOct 31, 2026 · stocktwits.com
- Teva Stock Has More Than Doubled in a Year. Where Will It Be in 3 Years?Oct 30, 2026 · fool.com
- Teva stock in focus after BXCL501 rights dealOct 30, 2026 · ad-hoc-news.de
- Bausch Health Soars 21% on Beat-and-Raise Quarter: Core EBITDA Hits a “First Time” MilestoneOct 29, 2026 · tikr.com
- What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q3 EarningsOct 29, 2026 · finance.yahoo.com
- Teva Acquires Worldwide Rights to BXCL501, Further Expanding Innovative Neuroscience PipelineOct 27, 2026 · finance.yahoo.com
- Zacks downgrades Teva stock to Strong Sell below yearly highOct 26, 2026 · ad-hoc-news.de
About Teva Pharmaceutical Industries Limited
Teva Pharmaceutical Industries Limited (TEVA) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in Israel. Its fiscal year ends in December.